February 15, 2018

drugNaltrexone may improve hyperactivity and restlessness in children with autism but there was not sufficient evidence that it had an impact on core features of autism in majority of the participants”.

That was the conclusions reached by Ashok Roy and colleagues* who looked at the collected data so far on the use of the opioid antagonist naltrexone in cases of pediatric autism.

More typically used to manage opioid and alcohol dependence, naltrexone belongs to a class of medicines which primarily act by blocking the opioid receptors we all have distributed in various parts of the body that are variably linked to feelings of euphoria, sedation and analgesia (pain relief).

With interest perhaps waning in naltrexone in recent years as a function of the myriad of other pharmacotherapeutics under investigation with autism in mind and the association between naltrexone use and hypotheses such as the opioid-excess theory of autism, the review by Roy and colleagues provides a timely reminder on the potential role of naltrexone for some people with autism.

Based on work started in the late 1970s hinting that there may overlap between some of the characteristics commonly observed in autism and that of opioid addiction, various research suggested there may be issues with some of the body’s own opioid-type chemicals called the endorphins in cases of autism. Coupled with speculation on the possible effects of external sources of opioid-like compounds derived from certain foods, naltrexone began to find some favour as an intervention option for autism, particularly where aggression and self-injury were common. The review by Roy and colleagues suggests that further investigations may be indicated on naltrexone in order to determine potential best-responders to this type of pharmacotherapy.

In more recent years, attention has also turned to the use of low-dose naltrexone (LDN) as a potential therapeutic option for autism following reports of successful use of lower doses of the drug for a variety of autoimmune related conditions such as Crohn’s disease. The implication being that one or more of the various immune system related findings highlighted in cases of autism, may offer additional targets for drugs such as naltrexone or that naltrexone may potentially be impacting on comorbid autoimmune conditions noted in some people with autism with a knock-on effect to behavioural symptoms. Further investigations are again required.

 

* Roy A. et al. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res. 2014 Mar 4.

Further commentary on this study can be found at: http://questioning-answers.blogspot.com/2014/04/new-life-for-naltrexone-and-autism.html

 

 

 

 

About the author 

Paul Whiteley Ph.D.

Researcher based in North East England. An academic background in psychology with a special interest in developmental psychology focused specifically on the autism spectrum and related conditions. Postgraduate degrees based on research examining the safety and efficacy of a gluten- and casein-free (GFCF) diet applied to autism and the potential importance of various comorbidity to the health and wellbeing of those on the autism spectrum, with a continuing research interest in these areas. Keen blogger and amateur science writer (but no formal qualifications in these areas). Science is based on probability.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

RELATED POSTS

December 24, 2020

From YouTube The United States Senate unanimously passed

November 6, 2020

Liver transplant potentially helpful in rare form of

October 6, 2020

New research conducted by a group of occupational

September 23, 2020

Pain may predict sleeping problems in teens diagnosed

July 15, 2020

A study published in The American Journal of

July 11, 2020

This is part 2 of our review of

June 22, 2020

It may seem like a pipe dream: a

June 4, 2020

CC BY by NIAID The results reported by

June 2, 2020

  On February 2, Autism Daily Newscast reported

>